Fascin acetylation modification as a tumor diagnosis and prognosis analysis marker, and detection reagent and application thereof

By using fascin K41 site acetylation modification as a marker, specific antibodies were developed, which addressed the shortcomings in esophageal cancer diagnosis and prognostic analysis, enabling precise diagnosis and prognostic analysis of esophageal cancer and providing a new method for targeted therapy.

CN116794309BActive Publication Date: 2026-07-24SHANTOU UNIV MEDICAL COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHANTOU UNIV MEDICAL COLLEGE
Filing Date
2022-11-07
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

Existing technologies lack effective methods for the diagnosis and/or prognostic analysis of esophageal cancer, especially since the key sites for the pro-cancer activity of fascin protein surface are still unclear, making it impossible to establish accurate tumor diagnosis and prognostic models and targeted therapies.

Method used

Using fascin K41 site acetylation modification as a biomarker, specific recognition antibodies were developed and applied through ELISA, Dot blot, Western blot and immunohistochemistry to establish a prognostic analysis model for esophageal cancer and targeted therapy.

Benefits of technology

It significantly inhibits the pro-cancer activity of fascin protein. By detecting the acetylation modification level at the K41 site, a prognostic analysis model for esophageal cancer was established, which can predict the risk of recurrence and metastasis and survival time of patients, and provide potential targets for targeted therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116794309B_ABST
    Figure CN116794309B_ABST
Patent Text Reader

Abstract

The present application relates to the field of tumor markers, in particular to a fascin acetylation modification which can be used as a tumor diagnosis and prognosis analysis marker, a detection reagent and application thereof. The present application is directed to the fact that acetylation modification at K41 site of fascin significantly inhibits the cancer-promoting activity of fascin protein, and in esophageal cancer tissue, the proportion of fascin with acetylation modification at K41 site is significantly lower than that of wild-type fascin in para-cancerous tissue. Based on the acetylation at K41 site of fascin, a specific antibody for acetylation at K41 site of fascin is developed, so as to conduct clinical application research on acetylation at K41 site of fascin, and establish an esophageal cancer prognosis analysis model and targeted treatment.
Need to check novelty before this filing date? Find Prior Art